Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib Before Allo-SCT in Myelofibrosis
NCT03645824Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jun 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pacritinib in myelofibrosis (MF), sponsored by HOVON. Started Jun 2018; status: active, not recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03645824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645824.